Navigation Links
Drug combination shrinks breast cancer metastases in brain
Date:12/17/2007

SAN ANTONIO, Texas--A combination of a "targeted" therapy and chemotherapy shrank metastatic brain tumors by at least 50 percent in one-fifth of patients with aggressive HER2-positive breast cancer, according to data presented by Dana-Farber Cancer Institute investigators at the San Antonio Breast Cancer Symposium.

Lapatinib (Tykerb) and capecitabine (Xeloda) were paired in an extension of a Phase 2 clinical trial in which lapatinib given alone shrank brain metastases significantly in six percent of 241 patients.

In the extension trial, capecitabine was added to lapatinib in 49 patients whose metastases -- cancerous colonies in the brain spread from their primary cancer -- had progressed while on treatment. With the combination therapy, brain metastases shrank by 20 percent or more in 18 patients (37 percent) and shrank by at least 50 percent in 10 patients (20 percent), reported Nancy Lin, MD, of Dana-Farber's Breast Oncology Center.

"Very few medications have shown activity in the treatment of brain metastases, particularly in HER-2-positive metastatic breast cancer patients," said Lin, who led the study with Eric Winer, MD, director of the Dana-Farber Breast Oncology Center. "Therefore, these data are quite encouraging, and further studies are warranted."

The data (abstract 6076) will be presented on Sunday, Dec. 16 at 7 a.m. CT.

Lapatinib is an oral small-molecule drug from GlaxoSmithKline that is approved along with capecitabine for treating patients with advanced or metastatic breast cancer whose tumors are driven by the abnormal growth signal, HER-2, and who have already undergone therapy including trastuzumab (Herceptin), a taxane drug, and an anthracycline compound. Lapatinib, like trastuzumab, blocks the HER-2 signal.

Up to one-third of women with advanced, HER-2-positive breast cancer may develop metastases to the brain.

"Although radiation treatment is often effective, as women live long
'/>"/>

Contact: Bill Schaller
william_schaller@dfci.harvard.edu
617-632-5357
Dana-Farber Cancer Institute
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Promising drug combination may help those with ocular melanoma that has spread
2. Combination therapy reverses effects of portal hypertension in rats
3. Combination vaccines okay for infants, study shows
4. Antidepressants and painkillers - a dangerous combination
5. Intra-arterial combination chemotherapy induces long-term survival for hepatocellular carcinoma
6. U.S. Oncology Initiates Complete Phase Ib Trial of Brostallicin Combination Therapy in Advanced Solid Tumors
7. Drug combination might offer hope for patients deadly brain tumors
8. EpiCept to Present Preclinical Studies of EPC2407 in Combination With Anti-Angiogenic and Chemotherpeutic Agents at the AACR-NCI-EORTC International Conference
9. Combination targets: some drugs may work best when they work together
10. MAP Pharmaceuticals Initiates Phase 2a Clinical Trial of Combination Therapy in Adult Patients with Asthma
11. Quality Control: Nissan Quest to Feature micronAir(R) Combination Cabin Air Filters
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/4/2015)... Los Angeles, CA (PRWEB) , ... September 04, 2015 , ... ... new material has been developed that changes color when subjected to an impact force ... article notes, could be implemented in helmets or other sporting equipment so that coaches ...
(Date:9/4/2015)... ... September 04, 2015 , ... The Schmidt National Law Group ... La Paz. , Schmidt National Law Group, a leading firm in mass-tort litigation, ... against Bayer Corp., Bayer Essure, Inc., and other Bayer affiliates for injuries alleged to ...
(Date:9/4/2015)... ... September 04, 2015 , ... Inmar announced ... joint meeting of its Product, Quality and Manufacturers, Dietary Supplements and Supply Chain ... evolving in the consumer goods industry, it can be difficult for companies to ...
(Date:9/4/2015)... ... 2015 , ... “Getting away from the daily stressors and distractions of life ... their ‘couple-ness,’” says Jean Claude Wietzel, general manager at Four Seasons Resort Maui ... only Forbes Five Star resort and Travel + Leisure’s No. 1 Hotel in Hawaii, ...
(Date:9/4/2015)... ... 2015 , ... The conference program for the upcoming Integrative ... 2015 at the Diplomat Resort & Spa has been announced and is available ... the top of their field and will be presenting sessions such as What ...
Breaking Medicine News(10 mins):Health News:New Article on Head Injury Detection Technology Highlights Implications for Head Injury Detection in Sports, says The Law Offices of Burg & Brock 2Health News:Schmidt National Law Group Files First Bayer Essure® Lawsuit in California 2Health News:Inmar Experts To Address OTC Manufacturers’ Session on Hazardous Waste and Handling at CHPA Meeting 2Health News:Inmar Experts To Address OTC Manufacturers’ Session on Hazardous Waste and Handling at CHPA Meeting 3Health News:Couples Season at Four Seasons Resort Maui Begins This Week With Best Hotel Rates of the Year through November 2Health News:Couples Season at Four Seasons Resort Maui Begins This Week With Best Hotel Rates of the Year through November 3Health News:Integrative Healthcare Symposium Focus On: The Microbiome Conference Program Announced 2
... Wash., Feb. 5 The number of Washington retailers illegally ... a new report. The annual rate of illegal sales was ... in 2007 and five percent in 2006. The state ... other state and local agencies to expand the effort to ...
... A Su Salud revealed high incidence of diabetes, osteoporosis, ... million in free and low cost medical services in ... -- CVS/pharmacy, the nation,s leading retail pharmacy, ... (To Your Health) health fairs, providing free health screenings ...
... Researchers from The University of Texas M. D. Anderson ... vessel formation, and vascular endothelial growth factor expression are ... ovarian tumors. This data was presented in a poster ... Annual Meeting on Women,s Cancer. , Sex cord-stromal ...
... Stephens Media LLC of,Las Vegas, Nevada entered ... to deliver Surgery Benefit Management to their health ... care and,personal savings through Healthplace America,s revolutionary surgery ... the Healthplace,Surgery Benefit(TM) is the first -- and ...
... company layoffs, job prospects for rehabilitation therapists ... is projected to increase demand for physical ... assistants up to 27 percent.KENNETT SQUARE, Pa., ... therapy industry continue to experience low rates ...
... Rice University,s Shepherd School of Music will bring together ... in human cognition and behavior for the Exploring the ... the dialogue between musicians and scientists, the conference events ... Shepherd School conference aims to be a trendsetter in ...
Cached Medicine News:Health News:More Retailers Selling Tobacco to Minors 2Health News:More Retailers Selling Tobacco to Minors 3Health News:CVS/pharmacy Launches 2009 'A Su Salud' Health Fairs Providing Free Health Screenings to the Community 2Health News:CVS/pharmacy Launches 2009 'A Su Salud' Health Fairs Providing Free Health Screenings to the Community 3Health News:Angiogenesis linked to poor survival in patients with rare type of ovarian cancer 2Health News:Stephens Media LLC Partners With Healthplace America to Enhance Employee Healthcare Benefits With Quality and Savings for Surgery 2Health News:Stephens Media LLC Partners With Healthplace America to Enhance Employee Healthcare Benefits With Quality and Savings for Surgery 3Health News:Stephens Media LLC Partners With Healthplace America to Enhance Employee Healthcare Benefits With Quality and Savings for Surgery 4Health News:Recession-Proof Your Career: High Job Growth Expected for Rehab Therapists 2Health News:Recession-Proof Your Career: High Job Growth Expected for Rehab Therapists 3Health News:Rice U. conference to explore music's role in human cognition and behavior 2Health News:Rice U. conference to explore music's role in human cognition and behavior 3
(Date:9/4/2015)... Future Prospects for Companies in Antihistamines, Corticosteroids, ... - new study showing you trends, partnerships, and ... allergic rhinitis drugs heading? What are the commercial prospects ... you potential revenues and other trends to 2025, discussing ... report provides 273 tables, charts, and graphs. Discover the ...
(Date:9/4/2015)... , Sep. 04, 2015 ... of the "Investigation Report on China,s Sodium Ibandronate Market, ... and used in the clinic under the trade name of ... Austria in 1996, sodium ibandronate was approved by ... treatment of osteoporosis under the trade name of Boniva. However, ...
(Date:9/4/2015)... September 4, 2015 Hutchison ... that Hutchison MediPharma Limited ("HMP"), its drug R&D ... second proof-of-concept ("POC") trial of fruquintinib in patients ... in China .  The top-line ... meeting the primary efficacy endpoint of progression free ...
Breaking Medicine Technology:Allergic Rhinitis Drugs Market Forecast 2015-2025 2Allergic Rhinitis Drugs Market Forecast 2015-2025 3Allergic Rhinitis Drugs Market Forecast 2015-2025 4Allergic Rhinitis Drugs Market Forecast 2015-2025 5Allergic Rhinitis Drugs Market Forecast 2015-2025 6Allergic Rhinitis Drugs Market Forecast 2015-2025 7Investigation Report on China's Sodium Ibandronate Market 2010-2019 2Second Proof-of-concept Trial of Fruquintinib Achieves its Primary Endpoint 2Second Proof-of-concept Trial of Fruquintinib Achieves its Primary Endpoint 3
... Late Stage Clinical Therapeutic Cancer... -- TUEBINGEN, Germany, September 21, 2010 ... ... ... ,; var first_result; // Results are keyed by longUrl, so we need to grab the first one. ...
... Inc., today announced that it reported positive preclinical ... Association for the Study of Diabetes (EASD).  CCX140, ... the chemokine receptor CCR2, improved metabolic function while ... in an animal model, and was well tolerated ...
Cached Medicine Technology:immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 2immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 3immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 4immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 5immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 6immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 7immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 8immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 9immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 10ChemoCentryx Reports Positive Results and Completion of Phase I Clinical Studies of Novel CCR2 Antagonist, CCX140, at the European Association for the Study of Diabetes (EASD) 2ChemoCentryx Reports Positive Results and Completion of Phase I Clinical Studies of Novel CCR2 Antagonist, CCX140, at the European Association for the Study of Diabetes (EASD) 3ChemoCentryx Reports Positive Results and Completion of Phase I Clinical Studies of Novel CCR2 Antagonist, CCX140, at the European Association for the Study of Diabetes (EASD) 4
... EXOGEN 2000+ device provides a non-invasive ... or the acceleration of fresh fracture ... for 20 minutes daily, or as ... physician determines your fracture to be ...
... growth stimulator is a useful adjunct for the ... or when patient compliance may be a concern. ... are assured of therapeutic treatment directly at the ... to 6 months. , ,The OsteoGen bone growth ...
... Interference Screw has unique, double-helix ... while limiting veering and divergence. ... abrasion where it is most ... thread enables screws to be ...
Cannulated Interference Screws...
Medicine Products: